Retinal vasculitis associated with intravitreal bevacizumab injection: A case report

dc.contributor.authorS. Murillo-Lopez
dc.contributor.authorSilvia Medina-Medina
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:22:50Z
dc.date.available2026-03-22T15:22:50Z
dc.date.issued2025
dc.descriptionCitaciones: 2
dc.description.abstractAnti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2<sup>nd</sup> dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.
dc.identifier.doi10.1016/j.oftale.2025.03.011
dc.identifier.urihttps://doi.org/10.1016/j.oftale.2025.03.011
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/52031
dc.language.isoes
dc.publisherElsevier BV
dc.relation.ispartofArchivos de la Sociedad Española de Oftalmología (English Edition)
dc.sourceCentro de Información y Desarrollo de la Mujer
dc.subjectBevacizumab
dc.subjectRetinal vasculitis
dc.subjectMedicine
dc.subjectOphthalmology
dc.subjectVasculitis
dc.subjectRetinal
dc.titleRetinal vasculitis associated with intravitreal bevacizumab injection: A case report
dc.typearticle

Files